We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Suppression of Cardiogenic Edema with Sodium–Glucose Cotransporter-2 Inhibitors in Heart Failure with Reduced Ejection Fraction: Mechanisms and Insights from Pre-Clinical Studies.
- Authors
Sullivan, Ryan D.; McCune, Mariana E.; Hernandez, Michelle; Reed, Guy L.; Gladysheva, Inna P.
- Abstract
In heart failure with reduced ejection fraction (HFrEF), cardiogenic edema develops from impaired cardiac function, pathological remodeling, chronic inflammation, endothelial dysfunction, neurohormonal activation, and altered nitric oxide-related pathways. Pre-clinical HFrEF studies have shown that treatment with sodium–glucose cotransporter-2 inhibitors (SGLT-2i) stimulates natriuretic and osmotic/diuretic effects, improves overall cardiac function, attenuates maladaptive cardiac remodeling, and reduces chronic inflammation, oxidative stress, and endothelial dysfunction. Here, we review the mechanisms and effects of SGLT-2i therapy on cardiogenic edema in various models of HFrEF. Overall, the data presented suggest a high translational importance of these studies, and pre-clinical studies show that SGLT-2i therapy has a marked effect on suppressing the progression of HFrEF through multiple mechanisms, including those that affect the development of cardiogenic edema.
- Subjects
VENTRICULAR ejection fraction; HEART failure; ENDOTHELIUM diseases; EDEMA; OXIDATIVE stress; BRAIN natriuretic factor
- Publication
Biomedicines, 2022, Vol 10, Issue 8, pN.PAG
- ISSN
2227-9059
- Publication type
Article
- DOI
10.3390/biomedicines10082016